Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Chemists’ Strike Seeks Halt To E-Pharmacy Sales

This article was originally published in PharmAsia News

Executive Summary

Pharmacies across India staged a one-day shutdown last week to demand a halt to e-pharmacy sales, becoming the latest retail group to oppose a booming online sector that is seen as threatening earnings of traditional bricks-and-mortar stores in the country.

You may also be interested in...



Indian E-Pharmacy 1mg Raises $70m, Plans Rapid Scale-up

India’s largest online pharmacy 1mg has raised $70m in its biggest funding round so far, led by Swiss investor Corisol with backing from the World Bank’s finance arm IFC. The company is planning a “rapid scale-up” with the aim of being the top integrated healthcare services provider in the country by 2023.

Share Fillip As Indian Pharma Crests US Regulatory Hump

For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.

Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial

Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.

Topics

UsernamePublicRestriction

Register

SC088444

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel